胰腺癌筛查:美国预防服务工作组更新版证据报告与系统综述
本系统综述评估了胰腺导管腺癌筛查的获益与危害,纳入13项前瞻性队列筛查研究(N=1317),主要在高家族风险人群中进行。影像学筛查在高家族风险人群中可检出胰腺导管腺癌且危害证据有限,但筛查对发病率与死亡率的影响尚未研究,平均风险人群无数据。
要点
- 在高家族风险人群中,影像学筛查可检出胰腺导管腺癌,且初始筛查未报告严重危害。
- 筛查对高家族风险人群发病率与死亡率的影响尚未研究,平均风险人群无数据。
- 筛查检出胰腺导管腺癌的手术干预获益与危害证据有限。
核心结论
- 在高家族风险人群中,影像学筛查可检出胰腺导管腺癌,且危害证据有限。
- 筛查对高家族风险人群发病率与死亡率的影响尚未研究,平均风险人群无数据。
- 筛查检出胰腺导管腺癌的手术干预获益与危害评估证据有限。
研究设计与样本
- 系统综述纳入13项质量尚可的前瞻性队列筛查研究,共1317名成人,主要在高家族风险人群中进行。
- 检索MEDLINE、PubMed和Cochrane对照试验注册库,时间从2002年1月至2018年4月27日,监测至2019年3月22日。
- 排除完全由已知与胰腺癌相关的遗传综合征人群组成的研究。
主要发现
- 使用内镜超声、磁共振成像和/或计算机断层扫描筛查的研究中,检出率范围为每1000人0至75例。
- 在1156名家族风险增加的成人中检出18例胰腺导管腺癌,在161名平均风险成人中检出0例。
- 8项研究(n=675)评估筛查操作危害,未报告初始筛查的严重危害。
- 2项研究(n=271)未发现与筛查相关的心理社会危害证据。
- 手术危害证据有限。
局限性
- 无研究报道筛查对发病率或死亡率的影响,也无研究报道筛查检出胰腺导管腺癌的治疗有效性。
- 无研究评估筛查试验的诊断准确性,所有13项研究仅报告检出率。
- 手术危害证据有限。
- 筛查对高家族风险人群发病率与死亡率的影响尚未研究,平均风险人群无数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pancreatic adenocarcinoma is the third most common cause of cancer death among men and women in the United States. OBJECTIVE: To systematically review benefits and harms of screening for pancreatic adenocarcinoma to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, PubMed, and the Cochrane Collaboration Registry of Controlled Trials, from January 2002 through April 27, 2018; surveillance through March 22, 2019. STUDY SELECTION: Studies of adults with or without risk factors for pancreatic adenocarcinoma (eg, family history of pancreatic cancer, personal history of new-onset diabetes) undergoing imaging-based screening; studies of treatment for adults with screen-detected or asymptomatic pancreatic adenocarcinoma. Included study designs were randomized clinical trials, nonrandomized controlled intervention studies, diagnostic accuracy studies with a reference standard, cohort studies, and case-control studies (for evaluation of harms only). Studies consisting entirely of populations with known genetic syndromes associated with pancreatic cancer were excluded. DATA EXTRACTION AND SYNTHESIS: Two investigators independently reviewed abstracts and full-text articles and rated included studies for quality; data were quantitatively analyzed to calculate a pooled diagnostic yield and narratively synthesized. MAIN OUTCOMES AND MEASURES: Mortality, morbidity, or quality of life; diagnostic accuracy of screening tests; any harm of screening or treatment. RESULTS: Thirteen fair-quality prospective cohort screening studies (N = 1317) conducted predominantly in populations at high familial risk for pancreatic adenocarcinoma were included. No studies reported on the effect of screening on morbidity or mortality or on the effectiveness of treatment for screen-detected pancreatic adenocarcinoma. Although no studies evaluated the diagnostic accuracy of screening tests, all 13 studies reported the diagnostic yield. Yields ranged from 0 to 75 cases per 1000 persons in studies using endoscopic ultrasound, magnetic resonance imaging, and/or computed tomography-based screening. In total, 18 cases of pancreatic adenocarcinoma were detected in 1156 adults at increased familial risk and 0 cases were detected in 161 average-risk adults. In 8 studies (n = 675) assessing procedural harms of screening, no serious harms from initial screening were reported. Two studies (n = 271) found no evidence of psychosocial harms related to screening. Evidence of surgical harms was limited. CONCLUSIONS AND RELEVANCE: Imaging-based screening in groups at high familial risk can detect pancreatic adenocarcinoma with limited evidence of minimal harms. However, the effect of screening on morbidity and mortality in groups at high familial risk has not been studied, and no data are available in average-risk populations. There is limited evidence to assess benefits or harms of surgical intervention for screen-detected pancreatic adenocarcinoma.
引用
- Henrikson NB, Aiello Bowles EJ, Blasi PR, et al. Screening for Pancreatic Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019. PMID: 31386140. doi:10.1001/jama.2019.6190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。